ANTICANCER COMBINATION THERAPY WITH CD73 ANTAGONIST ANTIBODY AND PD-1/PD-L1 AXIS ANTAGONIST ANTIBODY

摘要

Provided herein are methods for treating cancer, comprising administering to a subject having cancer a therapeutically effective amount of a CD73 antagonistic antibody alone or in combination with a PD-1/PD-L1 axis antagonist antibody.